Twist Bioscience Corp 8-K

What Happened

• Twist Bioscience Corporation announced its financial results for the quarter ended December 31, 2025 and filed a Current Report on Form 8-K on February 2, 2026 (Item 2.02).
• The company furnished the full text of the press release announcing those quarterly results as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: February 2, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Quarter covered: fiscal first quarter 2026 (quarter ended December 31, 2025).
• Press release title: “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results” — furnished as Exhibit 99.1.
• Interactive XBRL cover page furnished as Exhibit 104; report signed by Judy Yan, Assistant General Counsel and Assistant Secretary.

Why It Matters

• This 8-K signals that Twist has publicly released its quarterly earnings and other financial metrics; investors should review the press release (Exhibit 99.1) for revenue, earnings, cash flow, and any forward guidance or management commentary.
• The filing is a routine, timely disclosure of quarterly results under Item 2.02 and provides source documents (press release and Inline XBRL) that investors use to assess the company’s recent performance and update earnings expectations.